期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺转移瘤和第二原发癌的鉴别诊断与治疗

Different Diagnosis and Treatment of Metastatic Lung Cancer or Metachronous Primary Lung Cancer
下载PDF
导出
摘要 患者男性，47岁，因“肺癌综合治疗后2年余，再次术后1个月余”就诊。患者于2年余前CT定位下经皮肺穿刺活检（2007年12月18日）诊断：右上肺腺癌，伴有神经内分泌分化。免疫组化：CK7（＋＋＋），CK5／6（-），CK10／13（-），TTF-1（＋＋＋），
作者 廖日强 罗东兰 杨学宁
机构地区 广东省人民医院 广东省人民医院
出处 《循证医学》 CSCD 2011年第4期253-256,共4页 The Journal of Evidence-Based Medicine
关键词 肺转移瘤 第二原发癌 循证医学 病例讨论 metastatic lung cancer metachronous primary lung cancer evidence-based medicine clinical case conference
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1Shen KR, Meyers BF, Lamer JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) [J]. Chest, 2007,132 (3 Suppl): 290S-305S.
  • 2Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer [J]. Proc Am Thorac Soc, 2009,6(2):201-205.
  • 3Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies [J]. Lung Cancer. 2010.69 (3) : 272-278.
  • 4韩琤波,邹华伟,马洁韬,周洋,赵健竹.非小细胞肺癌原发灶和转移灶EGFR和KRAS状态比较的meta分析[J].中国肺癌杂志,2010,13(9):882-891. 被引量：8

二级参考文献39

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
  • 2Marsit CJ, Hasegawa M, Hirao T, et al. Loss ofheterozygosity of chromosome 3p21 is associated with mutant TPS3 and better patient survival in non sman-cell lung cancer. Cancer Res, 2004, 64(23): 8702-8707.
  • 3Garnis C, Lockwood WW, Vucic E, et al. High resolution analysis of nonsmall cell lung cancer cell lines by whole genome tiling path array CGH. IntJ Cancer, 2006, 118 (6): 1556-1564.
  • 4Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p 14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res, 2007, 67( 12): 5667-5672.
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361 (10): 947-957.
  • 6Massareni E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 2007, 13(10): 2890-2896.
  • 7Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005, 2(1 ): e 17.
  • 8Tsao MS, Zhu C, Sakurada A. An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment ofnon-smaU cell lung cancer.J Clin Oncol, 2006, 24(18S): 7005.
  • 9Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.J Clin Oncol, 2005, 23(28): 6838-6845.
  • 10Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol, 2006, 125(6): 860-865.

共引文献7

循证医学
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部